Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND 11314): a Phase I/II Clinical Trial

Next Previous
Trial Profile

Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND 11314): a Phase I/II Clinical Trial

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tagraxofusp (Primary)
  • Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 22 Dec 2025 According to Nippon Shinyaku media release, company has announced that the Ministry of Health, Labour and Welfare (MHLW) has approved ELZONRIS I.V. Injection (Tagraxofusp (genetically recombinant)) for the treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Japan.
  • 08 Oct 2019 According to a stemline media release, data from this study will be presented as an oral presentation at the 81st Annual Meeting of the Japanese Society of Hematology (JSH), to be held from October 11 and 13, 2019, at the Tokyo International Forum in Tokyo, Japan.
  • 09 May 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top